University of Pittsburgh researchers have developed novel HDAC 8 inhibitors based on indole amino ketones, which show promise for the treatment of kidney disease. These inhibitors are designed to target and modulate histone deacetylase (HDAC) activity, offering a potential therapeutic approach for managing kidney disease.